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Case Report
Abstract
Von Hippel Lindau (VHL) disease is a heritable cancer syndrome characterized by VHL gene mutation in 3p chromosome.
Mutations occur at the exons. Rarely mutations at introns have been reported. It leads to accumulation of Hypoxic ischemic
factor α (HIF α) which in turn leads to uncontrolled cellular proliferation. Few reports of pancreatic neuroendocrine tumors
(PNETs) are there in the literature. Most of them are associated with a mutation in the exon of VHL gene. Association with
intron mutation is not there. Here we are reporting a case of PNET in a patient who has a simultaneous mutation both at the
exon and the intron.
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Introduction
Gastro-enteropancreatic neuroendocrine tumors arise from
the neuroendocrine cells which are present diffusely in the
gastrointestinal tract.1 The cell type of the tumor is
heterogeneousin secreting various types of hormones or
being non-secreting at all.
On the basis of presence or absence of clinical syndrome due
to hormonal secretion, they are classified as functional or
non-functional.2 PNETs are rare pancreatic neoplasm with
unique tumor biology, presentation, and natural history in
contrast to the exocrine counterparts. PNETs occur most
commonly as sporadic but they can occur as a component of
specific genetic syndrome. Genetic syndromes which are
associated with PNETs are Multiple Endocrine Neoplasia 1
(MEN1), Von Hippel Lindau disease (VHL),
Neurofibromatosis 1 and Tuberous sclerosis.3
Case presentation
A 19 year old female presented to our outpatient department
with history of abdominal pain of 2 weeks duration. There
was associated history of early satiety. She was born of a
third degree consanguineous marriage. Three of her siblings
and her father had died due to cardiovascular diseases in
their second decade.
On examination she was found to have stage 1 blood
pressure according to Joint National Committee 8 with grade
1 hypertensive retinopathy. Rest of the systemic examination
was within normal limits. Hemogram and biochemistry were
essentially normal. Ultrasound abdomen revealed a mass in
the head of the pancreas. CT scan abdomen revealed mass in
the head of the pancreas which was hyperintense on contrast
study with a similar mass in the right adrenal gland (Figure 1
- 2). Urinary metanephrine levels were normal. I131 MIBG
scan showed no abnormal uptake in the adrenal glands. She
was started on antihypertensive medications. An exploratory
laparotomy was planned after the control of blood pressure.
Intra operatively the mass was found to be locally advanced
with extension to adrenals and surrounding structure.
Biopsy from the mass was taken which revealed WHO grade
2 neuroendocrine tumors (Figure 3 - 6). In view of family
history of sudden deaths and presence of pancreatic mass,
genetic testing for VHL mutation was done after genetic
counseling. Her mother refused to undergo the genetic
testing. The test results came positive for VHL gene mutation
both at exon3 and intron 1. MRI of the brain showed no
abnormality. She was started on tablet Sunitinib.
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FIG. 1: Ct scan showing a round irregular hyperenhancing lesion at
the head of the pancreas.
FIG. 2: Ct scan showing round hyperenhancing lesion in the right
adrena l gland.
FIG. 3: Small round cells arranged in clusters. No polymorphism is
noted.
FIG. 4: Immunohistochemistry with Ki 67 labelling index shows
positivity with less than 20%.
FIG. 5: Immunohistochemistry with chromatogrannin shows
positive staining.
FIG. 6: Immunohistochemistry with synaptophysin shows positive
staining.
Discussions
VHL disease is a heritable genetic disorder with incidence of
1 in 36,000 live births. 80% of the cases are heritable in an
autosomal dominant pattern, whereas the remaining cases
are acquired in a sporadic fashion.4 The syndrome is
characterized by the presence of either a single or
combination of tumors like cerebellar hemangioblastoma,
retinal angiomas, clear cell carcinomas of kidney, pancreatic
endocrine cysts and tumors, pheochromocytomas, and rarely
small cell carcinoma of lung and mesothelioma. On the basis
of clinical manifestation, VHL syndrome is classified as in
Table 1.
The VHL gene was first discovered in 1988 on short arm of
chromosome 3 (3p26-p25). Latiff et al., cloned the gene with
the establishment of its tumor suppressor activity in 1993.5
There is either somatic inactivation of the wild type of allele
or loss of heterozygosity of VHL gene or any of the
downstream genes which leads to disruption of the normal
function of the gene. VHL plays an important role in the
oxygen sensing pathway of the cell.6 The pathogenesis of
VHL syndrome is shown in Table 2.
Volume 3 • Number 4 • 2015 International Journal of Cancer Therapy and Oncology 3
www.ijcto.org
© Ganguly et al. ISSN 2330-4049
TABLE 1: Types of VHL syndrome.
VHL Type Characteristics
Type 1 Hemangioblastoma, with pheochromocytoma being rare.
Type 2A Pheochromocytoma with low risk of clear cell carcinoma and hemangioblastoma.
Type 2B Pheochromocytoma with high risk of clear cell carcinoma and hemangioblastoma.
Type 2C Familial pheochromocytoma with no risk of clear cell carcinoma and hemangioblastoma.
Type 3 Chuvas polycythemia.
TABLE 2: Pathogenesis of VHL syndrome.
Normally Pathologically ( mutation of VHL gene)
In presence of normal O2 tension,
VHL gene + E3 ubiquitin ligase
Proteosomal degradation of HIF α
Cellular homeostasis
In presence of normal O2 tension,
Mutated  VHL gene
(inhibits)
Proteosomal degradation of HIF α
Increased production of HIFα
Upregulation of VEGF pathway
Disruption of cellular homeostasis and development of neoplasm
Heterogeneous changes in amino acid residues lead to
alteration in the structure and function of protein which in
turn influences the disease phenotype. In our patient, there
were two heterozygous substitutions. One was a
heterozygous substitution of Cytosine to Thymine which
lead to change of amino acid Arginine to Tryptophan at
codon167 (p.Arg167Trp) in exon 3. This hotspot mutation
leads to diminish elongin binding. VHL proteins with
disruption of elongin binding are unstable and rapidly
degraded by proteasome which ultimately result in
tumorigenesis.7 Another heterozygous substitution
polymorphism was detected in intron 1 of VHL gene. As this
intronic variant occurs in splicing donor site, it affects the
efficiency of splicing and results in an unspliced transcript.
This has been detected in VHL families but its effect on
pathogenicity is not known.8
Patients can have abnormality in the nervous system,
cardiovascular system, adrenals pancreas and even
hematological. 77% of VHL patients can have involvement
of pancreas. Pancreatic involvement in VHL is diverse. The
most characteristic feature is the presence of pancreatic cyst
which includes simple cyst and serous cystadenomas. The
cysts don’t have any malignant potential. PNETs can be
found in 10-15% of VHL patients. They can occur in
isolation or associated with pancreatic cyst. PNETs have
malignant potential.9
TABLE 3: Grading of Pancreatic neuroendocrine tumor.
Grade Features
Low <2 mitoses/10hpf & Ki 67 index <3%
Intermediate 2-20 mitoses/10 hpf & Ki 67 index 3%-20%
High >20 mitoses/10hpf & Ki 67 index >20%
Primary modality of management for PNETs is surgical
excision and debulking if possible. There is no role of
adjuvant treatment if there is complete surgical excision
except in high grade tumors. In surgically inoperable cases,
chemotherapy plays a role. The choice of chemotherapeutic
agent depends on the grade of the tumor. They are divided
into low, intermediate and high grade depending on the
mitoses/high power field and Ki67 index as shown in Table
3.10 Low and intermediate grade tumors which are
inoperable or metastatic targeted therapies like somatostatin
analogues like octreotode, mTOR inhibitors like
everloimusor tyrosine kinase inhibitors like sunitinib are
used. Both everolimus and sunitinb are superior to
somatostatin analogues. However, there is no direct
comparison between the efficacy of everloimus and
sunitinib. High grades are treated by surgery upfront
followed by adjuvant chemotherapy, or neoadjuvant
chemotherapy followed by surgery. Combination of cisplatin
and etoposide is the most common chemotherapeutic agent
which is used in high grade variety. In view of grade 2
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inoperable tumor, patient was put on sunitinib and at
present she is doing well.
PNETs can have associations with genetic syndromes like
VHL. Management of the tumor depends on the surgical
operability and the grade of the tumor. There is no role of
adjuvant chemotherapy in low and intermediate grade
tumors. Targeted therapies like everolimus, sunitinib and
octreotide are useful for low and intermediate grade tumors.
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